Biosimilars and Future Biotherapeutics

Biosimilars in Oncology and Autoimmune Diseases

The transformative role of biosimilars in expanding access to life-saving biologic therapies for patients with cancer and chronic immune-mediated disorders. Oncology and autoimmune diseases represent two of the largest and most impactful therapeutic areas where biologics have revolutionized treatment paradigms. However, the high cost of reference biologic drugs has historically posed significant barriers to patient access, especially in resource-constrained healthcare systems. Biosimilars, with their comparable efficacy and safety at reduced costs, have emerged as a game-changing solution to improve treatment affordability and accessibility without compromising therapeutic outcomes. biosimilar use in conditions such as breast cancer, colorectal cancer, non-Hodgkin lymphoma, rheumatoid arthritis, psoriasis, ankylosing spondylitis, and inflammatory bowel disease. Special emphasis will be placed on biosimilars of monoclonal antibodies and targeted therapies such as trastuzumab, rituximab, bevacizumab, infliximab, adalimumab, and etanercept, which have already gained approval and widespread use across various regions. Attendees will gain insights into the design and outcomes of pivotal clinical trials supporting the approval of these biosimilars, as well as real-world evidence that demonstrates their effectiveness in clinical practice.